CN110812467A - 一种外用促进骨折康复的松桂香精油 - Google Patents
一种外用促进骨折康复的松桂香精油 Download PDFInfo
- Publication number
- CN110812467A CN110812467A CN201911276702.1A CN201911276702A CN110812467A CN 110812467 A CN110812467 A CN 110812467A CN 201911276702 A CN201911276702 A CN 201911276702A CN 110812467 A CN110812467 A CN 110812467A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- extraction
- mpa
- pressure
- separation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 198
- 235000017803 cinnamon Nutrition 0.000 title claims abstract description 39
- 230000001737 promoting effect Effects 0.000 title claims abstract description 25
- 235000008331 Pinus X rigitaeda Nutrition 0.000 title claims abstract description 17
- 241000018646 Pinus brutia Species 0.000 title claims abstract description 17
- 235000011613 Pinus brutia Nutrition 0.000 title claims abstract description 17
- 241000723347 Cinnamomum Species 0.000 title claims description 37
- 239000003814 drug Substances 0.000 claims abstract description 42
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 17
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 17
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 17
- 239000006002 Pepper Substances 0.000 claims abstract description 17
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 17
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 17
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 17
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract description 17
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 17
- 240000006927 Foeniculum vulgare Species 0.000 claims abstract description 16
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 16
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 16
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 16
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 16
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 16
- 235000008397 ginger Nutrition 0.000 claims abstract description 16
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 15
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 15
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 15
- 239000004863 Frankincense Substances 0.000 claims abstract description 15
- 240000001238 Gaultheria procumbens Species 0.000 claims abstract description 13
- 235000007297 Gaultheria procumbens Nutrition 0.000 claims abstract description 13
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940116229 borneol Drugs 0.000 claims abstract description 11
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 11
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 244000273928 Zingiber officinale Species 0.000 claims abstract 8
- 238000000605 extraction Methods 0.000 claims description 81
- 238000000926 separation method Methods 0.000 claims description 45
- 239000007788 liquid Substances 0.000 claims description 25
- 239000012530 fluid Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 18
- 241000722363 Piper Species 0.000 claims description 16
- 238000007873 sieving Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 241000209035 Ilex Species 0.000 claims description 3
- 244000150195 Cyperus longus Species 0.000 claims description 2
- 235000018109 Cyperus longus Nutrition 0.000 claims description 2
- 244000075634 Cyperus rotundus Species 0.000 claims description 2
- 235000005010 Scirpus paludosus Nutrition 0.000 claims description 2
- 235000003325 Ilex Nutrition 0.000 claims 1
- 239000011344 liquid material Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 2
- 244000203593 Piper nigrum Species 0.000 abstract 1
- 208000010392 Bone Fractures Diseases 0.000 description 52
- 206010017076 Fracture Diseases 0.000 description 51
- 210000000988 bone and bone Anatomy 0.000 description 41
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 19
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 206010061363 Skeletal injury Diseases 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 238000011552 rat model Methods 0.000 description 14
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 13
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000008439 repair process Effects 0.000 description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 241000234314 Zingiber Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000003423 ankle Anatomy 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 208000012661 Dyskinesia Diseases 0.000 description 4
- 244000242564 Osmanthus fragrans Species 0.000 description 4
- 235000019083 Osmanthus fragrans Nutrition 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000004821 effect on bone Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- 235000003332 Ilex aquifolium Nutrition 0.000 description 2
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 2
- 235000002294 Ilex volkensiana Nutrition 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 206010041569 spinal fracture Diseases 0.000 description 2
- 210000000273 spinal nerve root Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 206010010149 Complicated fracture Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010053206 Fracture displacement Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241001299553 Ilex chinensis Species 0.000 description 1
- 235000003366 Ilex purpurea Nutrition 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 101000762367 Rattus norvegicus Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101001052031 Rattus norvegicus Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000983304 Rattus norvegicus Osteocalcin Proteins 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000276425 Xiphophorus maculatus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Abstract
本发明涉及外用促进骨折康复的松桂香精油,可有效解决促进骨折康复的外用药物问题,其解决的技术方案是,由以下原料药物:桂枝精油8‑10mL、冬青精油5‑7mL、松节精油8‑10mL、川芎精油5‑7mL、生姜精油8‑10mL、小茴香精油8‑10mL、花椒精油8‑10mL、三七精油8‑10mL、乳香精油5‑7mL、大黄精油5‑7mL、香附精油5‑7mL和冰片22‑26g溶化混匀制成;本发明原料丰富,易生产制备,成本低,使用效果好,开拓了促进骨折康复的新药物,有显著的经济和社会效益。
Description
技术领域
本发明涉及医药,特别是一种外用促进骨折康复的松桂香精油。
背景技术
骨折是指骨结构的连续性完全或部分断裂。多见于儿童及老年人,中青年人也时有发生。病人常为—个部位骨折,少数为多发性骨折。经及时恰当处理,多数病人能恢复原来的功能,少数病人可遗留有不同程度的后遗症。
骨折的临床特有体征:
(1)畸形 骨折端移位可使患肢外形发生改变,主要表现为缩短、成角、延长。
(2)异常活动 正常情况下肢体不能活动的部位,骨折后出现不正常的活动。
(3)骨擦音或骨擦感 骨折后两骨折端相互摩擦撞击,可产生骨擦音或骨擦感。
以上三种体征只要发现其中之一即可确诊,但未见此三种体征者也不能排除骨折的可能,如嵌插骨折、裂缝骨折。一般情况下不要为了诊断而检查上述体征,因为这会加重损伤。
1.X线检查
凡疑为骨折者应常规进行X线拍片检查,可显示临床上难以发现的不完全性骨折、深部的骨折、关节内骨折和小的撕脱性骨折等,即使临床上已表现为明显骨折者,X线拍片检查也是必需的,可以了解骨折的类型和具体情况,对治疗具有指导意义。
2.CT检查
对于骨折不明确但又不能排除者、脊柱骨折有可能压迫脊髓神经根者及复杂骨折者均可行CT检查。三维CT重建可以更直观便捷地进行骨折分型,对治疗方案选择帮助很大,目前临床上常用。
3.MRI检查
虽然显示骨折线不如CT检查,但对于脊髓神经根及软组织损伤的显示有独特优点,目前已广泛用于脊柱骨折的检查。
骨折病人的典型表现是伤后出现局部变形、肢体等出现异常运动、移动肢体时可听到骨擦音。此外,伤口剧痛,局部肿胀、淤血,伤后出现运动障碍。
治疗骨折的最终目的是使受伤肢体最大限度的恢复功能,在骨折治疗中,其复位、固定、功能锻炼是骨折康复的三个基本治疗原则,目前作为骨折康复的药物有很多,如各种喷剂和口服剂,但由于种种原因,其使用并不尽人意,因此,研制新的促进骨折康复的新药物势在必行。
发明内容
针对上情况,为克服现有技术之缺陷,本发明之目的就是提供一种外用促进骨折康复的松桂香精油,可有效解决促进骨折康复的外用药物问题。
本发明解决的技术方案是,一种外用促进骨折康复的松桂香精油,由以下原料药物:桂枝精油8-10mL、冬青精油5-7mL、松节精油8-10mL、川芎精油5-7mL、生姜精油8-10mL、小茴香精油8-10mL、花椒精油8-10mL、三七精油8-10mL、乳香精油5-7mL、大黄精油5-7mL、香附精油5-7mL和冰片22-26g溶化混匀制成;其中:
所述的桂枝精油,是将桂枝粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,重量体积比是指固体以g计,液体以mL计,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得桂枝精油;
所述的冬青精油,是将冬青粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,重量体积比是指固体以g计,液体以mL计,以下同,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得冬青精油;
所述的松节精油,是将松节粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得松节精油;
所述的川芎精油,是将川芎粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得川芎精油;
所述的生姜精油,是将生姜粉碎,过10~20目筛,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得生姜精油;
所述的小茴香精油,是将小茴香粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得小茴香精油;
所述的花椒精油,是将花椒粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得花椒精油;
所述的三七精油,是将三七粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得三七精油;
所述的乳香精油,是将乳香粉碎,过10~20目筛,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得乳香精油;
所述的大黄精油,是将大黄粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得大黄精油;
所述的香附精油,是将香附粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得香附精油;
所述的冰片,是按药典要求的中药。
本发明原料丰富,易生产制备,成本低,使用效果好,开拓了促进骨折康复的新药物,有显著的经济和社会效益。
具体实施方式
以下结合实施例对本发明的具体实施方式作详细说明。
本发明在具体实施中可由以下实施例给出。
实施例1
本发明在具体实施中,一种外用促进骨折康复的松桂香精油,由以下原料药物:桂枝精油9mL、冬青精油6mL、松节精油9mL、川芎精油6mL、生姜精油9mL、小茴香精油9mL、花椒精油9mL、三七精油9mL、乳香精油6mL、大黄精油6mL、香附精油6mL和冰片24g溶化混匀制成。
实施例2
本发明在具体实施中,一种外用促进骨折康复的松桂香精油,由以下原料药物:桂枝精油8.5mL、冬青精油6.5mL、松节精油8.5mL、川芎精油6.5mL、生姜精油8.5mL、小茴香精油9.5mL、花椒精油8.5mL、三七精油9.5mL、乳香精油5.5mL、大黄精油6.5mL、香附精油5.5mL和冰片25g溶化混匀制成。
实施例3
本发明在具体实施中,一种外用促进骨折康复的松桂香精油,由以下原料药物:桂枝精油9.5mL、冬青精油5.5mL、松节精油9.5mL、川芎精油5.5mL、生姜精油9.5mL、小茴香精油8.5mL、花椒精油9.5mL、三七精油8.5mL、乳香精油6.5mL、大黄精油5.5mL、香附精油6.5mL和冰片23g溶化混匀制成。
松桂香精油所治为肝肾亏虚、寒邪壅滞所致的骨折迟愈合。方中桂枝散寒止痛、通阳化气与筋通络、祛风除湿的松节油共为君药,配以臣药生姜、小茴香精油和花椒精油温阳止痛,佐以大黄、三七、川芎活血散瘀,冬青精油入肝肾补肾强骨、香附精油疏肝解郁、调经止痛,并以乳香精油配以冰片清热解毒、消肿生肌,防止因伤口久不愈合导致肌溃肉腐。诸药共用而达活血通络,通阳止痛,散淤消肿之功。
本发明产品经实验和临床应用效果非常好,有关资料如下(以实施例1为例):
一、动物试验
1 实验材料
1.1 实验药品
正骨水(广西玉林制药集团有限责任公司,1711392),注射用青霉素钠(华北制药股份有限公司,批号F8088607),水合氯醛(天津市致远化学试剂有限公司,批号2019年03月20号),生理盐水(山东齐都药业有限公司,批号11B19021409),碘伏(德州欣瑞达消毒制品有限公司,批号190302),大鼠骨钙素(BGP)ELISA检测试剂盒(苏州卡尔文生物科技有限公司,批号LOT:20190602B),大鼠骨形成蛋白-2(BMP-2)ELISA检测试剂盒(苏州卡尔文生物科技有限公司,批号LOT:20190602B),大鼠碱性磷酸酶(ALP)ELISA检测试剂盒(苏州卡尔文生物科技有限公司,批号LOT:20190602B),大鼠成 纤维细胞生长因子-2(FGF-2)(苏州卡尔文生物科技有限公司,批号LOT:20190602B)。
本发明药物(实施例1产品)。
1.2 实验仪器
高速颅骨钻,型号STRONG 90;速冷冻离心机,型号KDC-160HR,科大创新股份有限公司中佳分公司;可调式移液器,型号JH30571,上海雷勃分析仪器有限公司;分析天平,型号AX324ZH,奥豪斯仪器(常州)有限公司;家用厨房秤,型号EK3820,广州香山衡器集团股份有限公司;宠物专用电推剪,型号CP-8000,深圳科德士电器有限公司;酶标仪,型号Cytation3,美国BIOTEK;全自动样品快速研磨仪,型号JXFSTPRP-24,上海净信实业发展有限公司。
1.3 实验动物
来自山东省实验动物中心的SPF级SD雄性大鼠,SPF级,性别:雄性,体重:200~220g,提供单位:济南朋悦实验动物繁育有限公司;动物合格证号:NO.37009200018689;实验伦理编号:DWLL2018030008;河南中医药大学动物实验中心许可证号:SYXK(豫)2015-0005。
2 实验方法
2.1 造模
SPF级SD大鼠,体重200~220g,雄性,随机选取12只作为空白对照组;除空白组12只大鼠外,其余大鼠用10%水合氯醛腹腔注射麻醉,剃去大鼠股骨桡侧皮肤被毛,剪开大鼠股骨桡侧皮层、肌肉层,暴露股骨,用直径1mm的高速路骨钻在股骨上钻直径1mm的缺损,喷洒青霉素钠注射液后逐层缝合。将大鼠放置于暖气片旁,待其苏醒后归笼。
2.2 用药方法
造模成功后,造模动物分为模型对照组,正骨水(正骨水药)组,松桂香精油大剂量组(200ul/只)、松桂香精油小剂量组(100ul/只)剂量组,每组均为12只。造模后前3天肌肉注射青霉素,防止出现感染。造模后第四天上午9:00开始在股骨桡侧皮肤涂抹精油给药,连续给精油28天。
2.3 观察项目及检测方法:
(1)血清中骨成型蛋白2(BMP-2)、成纤维细胞生长因子2(FGF-2)、碱性磷酸酶(ALP)、骨钙素(BGP)含量测定。
生物样品的制备:腹主动脉取血后,置于4℃药品阴凉柜中静置半小时后使用3000r/min的高速冷冻离心机离心10min,取血清后置于-20℃冰箱中保存,使用ELISA试剂盒测定生化指标。
(2)骨缺损修复程度评分
生物样品的制备:处死大鼠后使用剪刀、手术刀片,剪下大鼠造模处股骨,剥离肌肉、粘膜等组织,观察患处恢复情况。将骨折修复程度分为4个等级,(基本)正常(3分),明显修复(2分),略微修复(1分),无修复(0分)。
2.4 动物饲养
动物喂养时间:每天上午9:00喂养动物,换水、给饲料。
观察动物的时间及指标:上午10:00观察动物的活跃度、毛色、情绪。
禁食的方法:实验前1天晚10点禁食不禁水,禁食时换垫料。
3 实验结果
3.1 对骨损伤大鼠模型成纤维细胞生长因子-2(FGF-2)的影响
表1松桂香精油对骨损伤大鼠模型血清生长因子-2水平的影响(±s,n=12)
组别 | 只数 | FGF-2(pg/ml) |
空白组 | 12 | 225.43±79.59## |
模型组 | 12 | 386.12±93.98 |
正骨水组 | 12 | 610.4±99.39** |
松桂香精油大剂量 | 12 | 735.94±97.08** |
松桂香精油小剂量 | 12 | 452.43±198.69 |
注:空白组对比模型组##p<0.01,给药组对比模型组**p<0.01,*p<0.05
由表1可以看出,与空白组比,模型组血清生长因子-2水平显著升高(p<0.01);与模型组比,正骨水组和松桂香精油大剂量组血清FGF-2水平显著升高(p<0.01),松桂香精油小剂量组血清FGF-2水平有升高趋势(p<0.01)。
3.2 对骨损伤大鼠模型骨钙素(BGP)的影响
组别 | 只数 | BGP(ng/ml) |
空白组 | 12 | 6.88±2.54# |
模型组 | 12 | 4.36±1.99 |
正骨水组 | 12 | 11.35±7.49** |
松桂香精油大剂量 | 12 | 23.09±8.97** |
松桂香精油小剂量 | 12 | 6.99±3.98 |
注:空白组对比模型组##p<0.01,#p<0.05,给药组对比模型组**p<0.01,*p<0.05
由表2可知,与空白组比,模型组血清BGP水平明显降低(p<0.05);与模型组比,正骨水组和松桂香精油大剂量可显著升高血清BGP水平(p<0.01),松桂香精油小剂量有显著升高血清BGP水平的趋势(p>0.05)。
3.3 对骨损伤大鼠模型碱性磷酸酶(ALP)的影响
组别 | 只数 | ALP(IU/L) |
空白组 | 12 | 20.13±5.05## |
模型组 | 12 | 27.24±3.77 |
正骨水组 | 12 | 39.11±8.68** |
松桂香精油大剂量 | 12 | 47.62±11.5** |
松桂香精油小剂量 | 12 | 23.48±7.11 |
注:空白组对比模型组##p<0.01,给药组对比模型组**p<0.01
由表3可知,与空白组比,模型组血清ALP水平显著升高(p<0.01)。与模型组比,正骨水组和松桂香精油大剂量可显著升高血清ALP水平(p<0.01),松桂香精油小剂量仅升高血清ALP水平的趋势(p>0.05)。
3.4 对骨损伤大鼠模型骨成型蛋白2(BMP-2)的影响
组别 | 只数 | BMP-2(ng/ml) |
空白组 | 12 | 9.2±2.34# |
模型组 | 12 | 11.94±2.57 |
正骨水组 | 12 | 13.93±1.93* |
松桂香精油大剂量 | 12 | 23.39±9.49** |
松桂香精油小剂量 | 12 | 11.55±3.31 |
注:空白组对比模型组#p<0.05,给药组对比模型组**p<0.01,*p<0.05
与空白组比,模型组骨成型蛋白2(BMP-2)水平显著提高(p<0.01)。与模型组比,正骨水组可明显提升骨损伤大鼠模型骨成型蛋白2(BMP-2)含量(p<0.01),松桂香精油大剂量可显著提升骨损伤大鼠模型骨成型蛋白2(BMP-2)含量(p<0.01),松桂香精油小剂量仅有提升骨损伤大鼠模型骨成型蛋白2(BMP-2)含量的趋势(p>0.05)。
3.5 对骨损伤大鼠模型骨损伤处表观指标评分
组别 | 0 | 1 | 2 | 3 | P |
空白组 | 0 | 0 | 0 | 12 | ## |
模型组 | 7 | 5 | 0 | 0 | |
正骨水组 | 3 | 2 | 3 | 4 | * |
松桂香精油大剂量 | 0 | 1 | 2 | 9 | ** |
松桂香精油小剂量 | 5 | 1 | 1 | 5 |
注:空白组对比模型组##p<0.01,给药组对比模型组**p<0.01,*p<0.05
由表5可知,与空白组比,模型组可使大鼠模型骨质局部出现显著病变(p<0.01)。与模型组比,正骨水组较模型组有显著改善(p<0.05);松桂香精油大、小剂量组可使大鼠模型骨质局部显著改善(p<0.01)。
3.6 病理结果
病理结果可以明显观察到空白组骨密质骨呈板状,骨结构完整,骨组织无缺损,为正常骨组织;模型组骨小梁疏松,间隙较大,骨小梁周围有部分成骨细胞,成骨状态不活跃;正骨水组骨小梁间隙较模型组有明显缩小,骨小梁陷窝内有骨细胞,成骨状态较活跃;松桂香精油大剂量组骨小梁间隙最小,骨小梁融合形成板层骨,几乎完成损伤修复,效果最为明显;松桂香精油小剂量组骨小梁间隙较大,成骨状态不理想。
4 小结
骨折是日常生活中的常见疾病,很多因素都会导致骨折、骨裂等症状。骨折愈合是缓慢而又复杂的过程,需要多种因子的调控,促进骨折修复是临床上的难题。本实验采用钻孔法复制大鼠骨损伤模型,该方法可以明确控制孔洞直径,且模型恢复较快,便于观察实验结果。
在骨折愈合过程中,FGF-2能促进血管形成,诱导胚胎发育,促进神经生长,促使让软骨损伤修复,能促进骨膜血运,骨小梁重建和塑造更新加快,是评判骨状态的重要指标;BGP和ALP均为成骨细胞合成和分泌的并参与成骨过程,因此血清BGP和ALP水平可以反应出骨的形成和吸收的重要信息,是骨代谢的重要指标;BMP是目前最肯定的具有诱导成骨作用的生长因子,其中应用较多的有BMP-2和BMP-7,BMP-2是TGF-β的超家族成员,是目前已知的骨诱导能力最强的生长因子,其对骨生长、骨折愈合的作用已被证实,有极高的临床应用价值。
结合ELISA试剂盒结果、病理结果和表观指标评分综合判断,组松桂香精油组的效果明显优于正骨水药,对骨损伤的修复具有很好的促进作用,组松桂香精油大剂量组效果优于阳性对照。
二、临床试验
在动物试验确保安全的情况下,临床上又对骨折患者进行应用,取得了非常满意的疗效,具体资料如下:
对确诊的骨折患者年龄15~63 岁,其中男10例,女6例。均为骨科已采用石膏外固定或采用手法复位 +石膏外固定。给予常规抗感染、对症处理。随机分为本发明药物组(又称观察组)和对照组(每组8例)。观察组和对照组均在骨科采用石膏外固定或采用手法复位 +石膏外固定3 周后,观察组外用松桂香精油促骨折康复,局部外涂松桂香精油(外用局部无明显伤口),每日2-3次,每次0.2mL/cm2;7 天为1 个疗程,连续应用5周;患者早期应注意制动;疼痛减轻后即可开始踝关节的被动与主动活动度训练,肌肉的等张收缩,以及足趾、膝、髋关节的主动活动,但要限制踝关节跖屈,以免影响骨折稳定性。对照组不外涂精油,只进行普通锻炼康复。对照组自然恢复,除常规处理外,不再外用药物。
疗效标准 参照《中医病证诊断疗效标准》。显效:骨折解剖复位或接近解剖复位,有连续骨痂通过骨折线,功能完全或基本恢复;好转:对位良好,骨折线模糊,踝部轻度疼痛,劳累后加重,内外踝侧方骨折移位在2mm 以内,前后移位在2~4mm 以内,后踝向后上移位在2 ~5mm 之间;无效:对位差,踝部轻度或明显畸形,行走活动受限和疼痛,骨折移位致踝关节面不平整,骨折线清晰。
用药8周评价结果:观察组显效6例,占75%;好转2例,占25 %;无效0例。对照组显效3例,占37.5 %;好转4例,占50%;无效1例,占12.5 %;特别是显效,高达75%,明显高于对照组的37.5%,效果之好是未曾料到的。
在对实施例1做上述实验的同时,还对实施例2、3也做了同样的实验,均取得了相同和相近似的结果,表明产品质量好,疗效稳定可靠,这里不再一一列举。
结论
中医认为骨折归属“跌打损伤”范畴,认为骨折愈合是一个自然修复的过程,以瘀去、新生以及骨合为规律。肢体损于外,气血则伤于内,故外损内伤相互作用,致使在暴力作用下导致骨断筋离、气滞血瘀、经脉受损,而气滞血瘀,则阻塞经络,不通则痛,并且手术治疗具有一定创伤性,会加重局部肿痛,不利于患者术后肩关节功能恢复。因此,中医治疗应以调和气血、通经络、滋养筋骨为基本治疗原则。本发明松桂香精油:桂枝能发汗解肌,温通经脉;冬青可补肝强筋,补肾健骨;松节可疏通经络,活血止痛;川芎可活血祛瘀,通达止痛等;三七可活血化瘀,消肿止痛;花椒能温中行气,有补益作用,精油组方的用药符合中医理论,有效用于促进骨折的康复,是骨折康复外用药物上的一大创新,有显著的经济和社会效益。
Claims (4)
1.一种外用促进骨折康复的松桂香精油,特征在于,由以下原料药物:桂枝精油8-10mL、冬青精油5-7mL、松节精油8-10mL、川芎精油5-7mL、生姜精油8-10mL、小茴香精油8-10mL、花椒精油8-10mL、三七精油8-10mL、乳香精油5-7mL、大黄精油5-7mL、香附精油5-7mL和冰片22-26g溶化混匀制成;其中:
所述的桂枝精油,是将桂枝粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,重量体积比是指固体以g计,液体以mL计,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得桂枝精油;
所述的冬青精油,是将冬青粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,重量体积比是指固体以g计,液体以mL计,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得冬青精油;
所述的松节精油,是将松节粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得松节精油;
所述的川芎精油,是将川芎粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得川芎精油;
所述的生姜精油,是将生姜粉碎,过10~20目筛,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得生姜精油;
所述的小茴香精油,是将小茴香粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得小茴香精油;
所述的花椒精油,是将花椒粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得花椒精油;
所述的三七精油,是将三七粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得三七精油;
所述的乳香精油,是将乳香粉碎,过10~20目筛,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得乳香精油;
所述的大黄精油,是将大黄粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得大黄精油;
所述的香附精油,是将香附粉碎成过10~20目筛的粗粉,超临界CO2流体萃取,液料重量体积比1:10~20,萃取温度42~50℃,萃取压力20~25MPa,分离温度50~60℃,分离压力4.5~5.5MPa,萃取时间1.5~2.5h,得香附精油。
2.根据权利要求1所述的外用促进骨折康复的松桂香精油,其特征在于,由以下原料药物:桂枝精油9mL、冬青精油6mL、松节精油9mL、川芎精油6mL、生姜精油9mL、小茴香精油9mL、花椒精油9mL、三七精油9mL、乳香精油6mL、大黄精油6mL、香附精油6mL和冰片24g溶化混匀制成。
3.根据权利要求1所述的外用促进骨折康复的松桂香精油,其特征在于,由以下原料药物:桂枝精油8.5mL、冬青精油6.5mL、松节精油8.5mL、川芎精油6.5mL、生姜精油8.5mL、小茴香精油9.5mL、花椒精油8.5mL、三七精油9.5mL、乳香精油5.5mL、大黄精油6.5mL、香附精油5.5mL和冰片25g溶化混匀制成。
4.根据权利要求1所述的外用促进骨折康复的松桂香精油,其特征在于,由以下原料药物:桂枝精油9.5mL、冬青精油5.5mL、松节精油9.5mL、川芎精油5.5mL、生姜精油9.5mL、小茴香精油8.5mL、花椒精油9.5mL、三七精油8.5mL、乳香精油6.5mL、大黄精油5.5mL、香附精油6.5mL和冰片23g溶化混匀制成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911276702.1A CN110812467A (zh) | 2019-12-12 | 2019-12-12 | 一种外用促进骨折康复的松桂香精油 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911276702.1A CN110812467A (zh) | 2019-12-12 | 2019-12-12 | 一种外用促进骨折康复的松桂香精油 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110812467A true CN110812467A (zh) | 2020-02-21 |
Family
ID=69545128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911276702.1A Pending CN110812467A (zh) | 2019-12-12 | 2019-12-12 | 一种外用促进骨折康复的松桂香精油 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110812467A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101862419A (zh) * | 2009-04-20 | 2010-10-20 | 刘明林 | 治疗闭合性骨伤的外用药 |
CN107213225A (zh) * | 2017-05-17 | 2017-09-29 | 杨宇 | 一种用于止痛、促进骨生长的药物组合物及其应用 |
CN108066541A (zh) * | 2016-11-18 | 2018-05-25 | 天津市晨洁华美科技发展有限公司 | 一种骨科用膏药的制备方法 |
CN108837132A (zh) * | 2018-09-06 | 2018-11-20 | 河南中医药大学 | 一种治疗血管闭塞性脉管炎的中药精油 |
-
2019
- 2019-12-12 CN CN201911276702.1A patent/CN110812467A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101862419A (zh) * | 2009-04-20 | 2010-10-20 | 刘明林 | 治疗闭合性骨伤的外用药 |
CN108066541A (zh) * | 2016-11-18 | 2018-05-25 | 天津市晨洁华美科技发展有限公司 | 一种骨科用膏药的制备方法 |
CN107213225A (zh) * | 2017-05-17 | 2017-09-29 | 杨宇 | 一种用于止痛、促进骨生长的药物组合物及其应用 |
CN108837132A (zh) * | 2018-09-06 | 2018-11-20 | 河南中医药大学 | 一种治疗血管闭塞性脉管炎的中药精油 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100423761C (zh) | 一种治疗骨折、跌打损伤的中药制剂 | |
CN105616824A (zh) | 一种接骨续筋膏药及其制备方法 | |
CN100484538C (zh) | 上、中、下部汤及其制备方法 | |
CN101352506B (zh) | 一种治疗骨科疾病的药物及其制备方法和应用 | |
CN104800443B (zh) | 一种补肾生髓续骨剂 | |
CN110812467A (zh) | 一种外用促进骨折康复的松桂香精油 | |
CN103191315B (zh) | 一种治疗绝经后骨质疏松症的中药 | |
CN1332677C (zh) | 一种治疗骨伤的药物 | |
CN102091204B (zh) | 治疗跌打损伤、深部静脉炎的中药组合物及其制法与应用 | |
CN103735851A (zh) | 一种治疗骨折的中药制剂 | |
CN108186995A (zh) | 正骨膏药 | |
CN1438006A (zh) | 一种治疗骨科疾病的药物 | |
CN106421098B (zh) | 治疗多种骨病的外用中药组合物 | |
CN107929636A (zh) | 一种治疗疼痛的中药喷剂及其制备方法 | |
CN114558088B (zh) | 一种治疗原发性骨质疏松症的蒙药复方及其应用 | |
CN102258762B (zh) | 一种消肿止痛的药物组合物及其制剂和应用 | |
CN102512505B (zh) | 一种治疗骨刺的中成药 | |
CN107773615A (zh) | 一种治疗骨折延迟愈合的中药组合物 | |
CN1887331A (zh) | 张氏接骨散 | |
CN105434818A (zh) | 治疗颈椎病的中药制剂 | |
CN108210697A (zh) | 一种用于治疗骨质增生的外用药膏及其制备方法 | |
CN104474110A (zh) | 一种治疗老年骨性关节炎的药物 | |
CN104644732B (zh) | 一种治疗肝肾不足型绝经后骨质疏松症的中药制剂 | |
CN104435329A (zh) | 一种治疗跟骨高压症的中药组合物 | |
CN111714528A (zh) | 一种减缓骨质流失、维持骨骼密度的组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200221 |